What's Happening?
Momentum Biotechnologies, a contract research organization specializing in mass spectrometry for drug discovery, has launched a new technology called CHIPP (chaotrope-induced protein precipitation and proteome profiling). This innovative, label-free assay
is designed to analyze drug-target interactions with high sensitivity and scalability. CHIPP allows for automated, proteome-wide profiling of numerous test compounds, enhancing the capacity for target identification, deconvolution, and selectivity profiling. According to Hannes Hahne, President of Momentum's European operations, CHIPP significantly increases both the depth and throughput of target deconvolution compared to existing methods. This advancement enables scientific teams to gather more comprehensive data on a larger number of compounds in a shorter time frame. The technology is expected to accelerate drug discovery workflows by allowing researchers to analyze hundreds of primary screening hits in a 96-well-plate format.
Why It's Important?
The introduction of CHIPP by Momentum Biotechnologies represents a significant advancement in the field of drug discovery. By enabling more comprehensive and rapid analysis of drug-target interactions, CHIPP has the potential to streamline the drug development process. This could lead to faster identification and validation of therapeutic leads, ultimately accelerating the development of new treatments. The ability to analyze a larger number of compounds efficiently could also reduce costs and improve the success rate of drug discovery projects. This development is particularly relevant for biopharmaceutical companies seeking to enhance their research capabilities and bring new drugs to market more quickly.
What's Next?
Momentum Biotechnologies plans to showcase CHIPP at the upcoming American Society for Mass Spectrometry conference in San Diego, California. This event, scheduled from May 31 to June 4, 2026, will provide an opportunity for researchers to learn more about the applications of CHIPP in drug discovery and development. Momentum's scientific team will be available to discuss the technology and its potential benefits with interested parties. The company is also encouraging researchers to connect through their website or via email for further information. As CHIPP gains traction, it is likely to attract interest from a wide range of biopharmaceutical clients looking to enhance their drug discovery processes.
